Keep up-to-date with the latest news, events and industry insights.
There are times in our professional lives when we are looking for a job change. When this search leads to ADAMAS, it may prompt the question, “Why is working at ADAMAS a good decision?” It might be beneficial to hear the perspective of a current employee, something...read more
We would like to thank you all for following our blog over the course of the last year and hope you will continue to do so in 2017. Please click the link below to see our Christmas Card. Click here to see the ADAMAS Christmas Card Hoping you all have a Merry Christmas...read more
The Medicines and Healthcare products Regulatory Agency (MHRA) recently published their latest Good Pharmacovigilance Practice (GVP) Inspection metrics covering the period April 2015 – March 2016. Within this period a total of 35 inspections had been carried out,...read more
The ICH E6 (R2) has been formally adopted by the ICH assembly held in Osaka, Japan on 5-10 November 2016. All changes proposed in ICH E6 (R2) Step 2 have been accepted in principle, within the ICH E6 (R2) guideline during Step 4 adoption by the ICH Assembly. A...read more
“The RQA 2016 Annual Conference will be held at the Hilton Brighton Metropole 9-11 November 2016” Representing ADAMAS at this year’s RQA Conference will be Carly Davenport and Ian Brady, Heads of our Global CSV and GVP practices. Carly and Ian look forward to meeting...read more
ADAMAS Consulting (ADAMAS) is one of the world’s leading global providers of research Quality Assurance (QA) services offering auditing and consulting resources for all of the Good Practices (GxPs, where x is Clinical, Laboratory, Manufacturing, Distribution and...read more
ADAMAS was born (officially) on 1st September 1997, the year when the ‘new’ ICH GCP Guidelines were released – a happy coincidence in fact! Looking back, I can hardly believe we have been in business this long, and we’re still growing and expanding, which is the sign...read more
The Indian Central Drugs Standard Control Organization (CDSCO) relaxes two crippling restrictions imposed since 2014!
According to the Office Order dated 03-Jul-14 issued by the CDSCO, a Principal Investigator could not conduct more than three (03) clinical trials at any given period of time, irrespective of whether those clinical trials were actively recruiting or were in long term...read more
In Apr-13, the Medicines and Healthcare products Regulatory Agency (MHRA) successfully prosecuted an individual for manipulating pre-clinical analytical data. Following identification of irregularities in the bioanalytical data, the MHRA was notified and the following...read more
“DIA 2016 52nd Annual Meeting is the largest global interdisciplinary event that brings together 7,000+ key thought leaders and innovators from industry, academia, regulatory and government agencies, health, patient, and philanthropic organizations from around the...read more